Aa
RNA Undetectable at 4 weeks...
So I have good news! I went from 10,000,000 to zero RNA after 4 weeks! I am also on the Bocifovir trials for people who did not respond to Peg & Riba the first time around. I started the big blue pills last week. It seems like all I do is take pills...Anyway,I do have a question buried in all of this: It seems like before the big blues, I would start to regain my energy about the second day after taking the Peg shot. Now, it is the forth day and I still feel poorly. According to the liturature, the only side effect are supposed to be headache, metallic taste, and stomach problems. Is anyone else experiencing additional fatigue and nausea?
The drop to zero RNA was after the 4 week lead in with Peg & Riba only. I hadn't even started the Boceprevir until after I got these results from my nurse. Like I said though, I had to have had the same response when I did this the first time a year and a half ago. Apparently I went clean after the first month, stayed good for nine more, then it came back after end of treatment. All my hopes today are on the BOC. Incidentally, does anyone in the BOC trial burp up a nasty aftertaste after eating the big blue pills. I'm still trying to assure myself that I'm not getting the placebo. Thnks for all the responses!
Thats what I call a drop!!!!
Im a bit curious though same as rocker, I thought you first in this trial was taking soc for 4 weeks then started with the other meds am i right here, if you please clarify.
In any case its a great result big congrats.
About the sx its sounds as regular soc sx thats use to increase for many about 3,4,5 weeks into treatment.
God bless.
ca
Im a bit curious though same as rocker, I thought you first in this trial was taking soc for 4 weeks then started with the other meds am i right here, if you please clarify.
In any case its a great result big congrats.
About the sx its sounds as regular soc sx thats use to increase for many about 3,4,5 weeks into treatment.
God bless.
ca
CONGRATS on the UND at 4 weeks. i got that kind of good news myself last monday. im UND at 5 weeks. first time on tx for me though and i had gotten lucky, mine is was type 2b. congrats again. great news!!!!!!!.
im keeping everyone in my prayers. i hope everyone can be so lucky as to become UND. much love to all.
irish
im keeping everyone in my prayers. i hope everyone can be so lucky as to become UND. much love to all.
irish
i am also in the BOC non-responder trial...
YOU SAID:I went from 10,000,000 to zero RNA after 4 weeks!
is this after 4 weeks on the BOC drugs....or 4 weeks after the SOC drugs???
YOU SAID:I went from 10,000,000 to zero RNA after 4 weeks!
is this after 4 weeks on the BOC drugs....or 4 weeks after the SOC drugs???
Wow you have great results, this latest study shows you have a great chance at SVR being a RVR. Also you seem to be having the normal sxs.
• The most common adverse events (AEs) reported in the boceprevir arms were fatigue, anemia, nausea, and headache.
• AEs occurred at similar rates in the boceprevir and standard therapy arms with the exception of anemia, which was more common with boceprevir.
• Incidence of rash and pruritis (itching) were similar with the boceprevir regimens and standard therapy.
KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The compound, known as SCH 900518 is currently in Phase IIa clinical development. The update was presented today as part of the company's 2008 R&D Update meeting at its headquarters in Kenilworth, N.J.
"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.
The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received the boceprevir P/R lead-in regimen and had rapid virologic response (RVR), defined as undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment, SVR was 94 percent in the 48 week regimen and 82 percent in the 28-week regimen. RVR has been shown to be a reliable predictor for achieving SVR. These final results are from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
----------------------------------------------------------------------------------------------------
Notice the RVR rate with 4 weeks of BOC.... SVR was 94 percent for 48 weeks and 82 percent for 28
Best to you
• The most common adverse events (AEs) reported in the boceprevir arms were fatigue, anemia, nausea, and headache.
• AEs occurred at similar rates in the boceprevir and standard therapy arms with the exception of anemia, which was more common with boceprevir.
• Incidence of rash and pruritis (itching) were similar with the boceprevir regimens and standard therapy.
KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhibitor currently in Phase III development. The company believes boceprevir has the potential to be a first-in-class and best-in-class protease inhibitor for treating chronic hepatitis C. The company also announced that it is developing a highly potent next-generation oral hepatitis C protease inhibitor that has future best-in-class potential. The compound, known as SCH 900518 is currently in Phase IIa clinical development. The update was presented today as part of the company's 2008 R&D Update meeting at its headquarters in Kenilworth, N.J.
"As pioneers in the hepatitis field, our vision is to apply our experience and innovation, as we have in the past, to continue to redefine and improve treatments for chronic hepatitis C, in the near term and in the future," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute.
The company reported for the first time that in a Phase II study, a 48-week boceprevir regimen achieved an unprecedented 75 percent sustained virologic response (SVR) rate at 24 weeks after the end of treatment (SVR 24) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) (P/R lead-in). This represents a near doubling of the 38 percent SVR 24 rate for patients in the control group receiving 48-weeks of PEGINTRON and REBETOL alone (ITT).(1,2) In a 28-week boceprevir P/R lead-in regimen, the SVR 24 rate was 56 percent. Importantly, for patients who received the boceprevir P/R lead-in regimen and had rapid virologic response (RVR), defined as undetectable virus (HCV-RNA) in plasma after 4 weeks of boceprevir treatment, SVR was 94 percent in the 48 week regimen and 82 percent in the 28-week regimen. RVR has been shown to be a reliable predictor for achieving SVR. These final results are from the HCV SPRINT-1 study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.
----------------------------------------------------------------------------------------------------
Notice the RVR rate with 4 weeks of BOC.... SVR was 94 percent for 48 weeks and 82 percent for 28
Best to you
Great news! That's a fabulous result!
Since you're in a study, are you having weekly labwork done? Some of the new drugs added to SOC tx also cause an increase in anemia, which is what happened to me. My Hgb dropped from 13.9 to 9.7 in a 3-week period, and I experienced severe fatigue and nausea. I didn't realize it was because I had suddenly become anemic. I don't know if this is one of the side effects of Boceprevir, but if it is, it could help to explain how you're feeling. You may want to ask about your Hgb results when you have your next study visit, and be sure to tell them what you've experienced.
Best of luck with your tx.
Since you're in a study, are you having weekly labwork done? Some of the new drugs added to SOC tx also cause an increase in anemia, which is what happened to me. My Hgb dropped from 13.9 to 9.7 in a 3-week period, and I experienced severe fatigue and nausea. I didn't realize it was because I had suddenly become anemic. I don't know if this is one of the side effects of Boceprevir, but if it is, it could help to explain how you're feeling. You may want to ask about your Hgb results when you have your next study visit, and be sure to tell them what you've experienced.
Best of luck with your tx.
That's incredible! Congratulations!!
Gives me hope, even though I'm not on any trial. My viral load three weeks before starting tx was 2.6 million, geno3.
Gives me hope, even though I'm not on any trial. My viral load three weeks before starting tx was 2.6 million, geno3.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
